FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103647780> ?p ?o ?g. }

• W2103647780 endingPage "2006" @default.
• W2103647780 startingPage "1995" @default.
• W2103647780 abstract "Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases serum LDL-cholesterol (LDL-C) concentrations. We assessed the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients with hypercholesterolaemia in the absence of concurrent lipid-lowering treatment.In a phase 2 trial done at 52 centres in Europe, the USA, Canada, and Australia, patients (aged 18-75 years) with serum LDL-C concentrations of 2·6 mmol/L or greater but less than 4·9 mmol/L were randomly assigned equally through an interactive voice response system to subcutaneous injections of AMG 145 70 mg, 105 mg, or 140 mg, or placebo every 2 weeks; subcutaneous AMG 145 280 mg, 350 mg, or 420 mg or placebo every 4 weeks; or oral ezetimibe 10 mg/day. The primary endpoint was percentage change from baseline in LDL-C concentration at week 12. Analysis was by modified intention to treat. Study personnel and patients were masked to treatment assignment of AMG 145 or placebo. Ezetimibe assignment was open label. This trial is registered with ClinicalTrials.gov, number NCT01375777.406 patients were assigned to AMG 145 70 mg (n=45), 105 mg (n=46), or 140 mg (n=45) every 2 weeks; AMG 145 280 mg (n=45), 350 mg (n=45), or 420 mg (n=45) every 4 weeks; placebo every 2 weeks (n=45) or every 4 weeks (n=45); or ezetimibe (n=45). AMG 145 significantly reduced LDL-C concentrations in all dose groups (mean baseline LDL-C concentration 3·7 mmol/L [SD 0·6]; changes from baseline with every 2 weeks AMG 145 70 mg -41·0% [95% CI -46·2 to -35·8]; 105 mg -43·9% [-49·0 to -38·7]; 140 mg -50·9% [-56·2 to -45·7]; every 4 weeks AMG 145 280 mg -39·0% [-44·1 to -34·0]; 350 mg -43·2% [-48·3 to -38·1]; 420 mg -48·0% [-53·1 to -42·9]; placebo every 2 weeks -3·7% [-9·0 to 1·6]; placebo every 4 weeks 4·5% [-0·7 to 9·8]; and ezetimibe -14·7% [-18·6 to -10·8]; p<0·0001 for all doses vs placebo or ezetimibe). Treatment-emergent adverse events occurred in 136 (50%) of 271 patients in the AMG 145 groups, 41 (46%) of 90 patients in the placebo groups, and 26 (58%) of 45 patients in the ezetimibe group; no deaths or serious treatment-related adverse events were reported.The results of our study support the further assessment of AMG 145 in long-term studies with larger and more diverse populations including patients with documented statin intolerance.Amgen." @default.
• W2103647780 created "2016-06-24" @default.
• W2103647780 creator A5020693718 @default.
• W2103647780 creator A5032891959 @default.
• W2103647780 creator A5039360390 @default.
• W2103647780 creator A5043191335 @default.
• W2103647780 creator A5045290077 @default.
• W2103647780 creator A5068236757 @default.
• W2103647780 creator A5080563770 @default.
• W2103647780 creator A5086317157 @default.
• W2103647780 date "2012-12-01" @default.
• W2103647780 modified "2023-10-12" @default.
• W2103647780 title "Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study" @default.
• W2103647780 cites W1972661406 @default.
• W2103647780 cites W1987478572 @default.
• W2103647780 cites W2010033213 @default.
• W2103647780 cites W2028219942 @default.
• W2103647780 cites W2040612932 @default.
• W2103647780 cites W2057355562 @default.
• W2103647780 cites W2058019883 @default.
• W2103647780 cites W2067539811 @default.
• W2103647780 cites W2071154679 @default.
• W2103647780 cites W2096075279 @default.
• W2103647780 cites W2102764767 @default.
• W2103647780 cites W2103873642 @default.
• W2103647780 cites W2105119801 @default.
• W2103647780 cites W2106343349 @default.
• W2103647780 cites W2106759269 @default.
• W2103647780 cites W2119646994 @default.
• W2103647780 cites W2128030263 @default.
• W2103647780 cites W2133071863 @default.
• W2103647780 cites W2141191772 @default.
• W2103647780 cites W2160936671 @default.
• W2103647780 cites W2165924268 @default.
• W2103647780 cites W2247997571 @default.
• W2103647780 cites W2330843213 @default.
• W2103647780 cites W4230870013 @default.
• W2103647780 doi "https://doi.org/10.1016/s0140-6736(12)61771-1" @default.
• W2103647780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23141812" @default.
• W2103647780 hasPublicationYear "2012" @default.
• W2103647780 type Work @default.
• W2103647780 sameAs 2103647780 @default.
• W2103647780 citedByCount "306" @default.
• W2103647780 countsByYear W21036477802012 @default.
• W2103647780 countsByYear W21036477802013 @default.
• W2103647780 countsByYear W21036477802014 @default.
• W2103647780 countsByYear W21036477802015 @default.
• W2103647780 countsByYear W21036477802016 @default.
• W2103647780 countsByYear W21036477802017 @default.
• W2103647780 countsByYear W21036477802018 @default.
• W2103647780 countsByYear W21036477802019 @default.
• W2103647780 countsByYear W21036477802020 @default.
• W2103647780 countsByYear W21036477802021 @default.
• W2103647780 countsByYear W21036477802022 @default.
• W2103647780 countsByYear W21036477802023 @default.
• W2103647780 crossrefType "journal-article" @default.
• W2103647780 hasAuthorship W2103647780A5020693718 @default.
• W2103647780 hasAuthorship W2103647780A5032891959 @default.
• W2103647780 hasAuthorship W2103647780A5039360390 @default.
• W2103647780 hasAuthorship W2103647780A5043191335 @default.
• W2103647780 hasAuthorship W2103647780A5045290077 @default.
• W2103647780 hasAuthorship W2103647780A5068236757 @default.
• W2103647780 hasAuthorship W2103647780A5080563770 @default.
• W2103647780 hasAuthorship W2103647780A5086317157 @default.
• W2103647780 hasConcept C126322002 @default.
• W2103647780 hasConcept C126894567 @default.
• W2103647780 hasConcept C134018914 @default.
• W2103647780 hasConcept C142724271 @default.
• W2103647780 hasConcept C197934379 @default.
• W2103647780 hasConcept C203092338 @default.
• W2103647780 hasConcept C204787440 @default.
• W2103647780 hasConcept C27081682 @default.
• W2103647780 hasConcept C2778163477 @default.
• W2103647780 hasConcept C2778375690 @default.
• W2103647780 hasConcept C2778657065 @default.
• W2103647780 hasConcept C2778849439 @default.
• W2103647780 hasConcept C2780072125 @default.
• W2103647780 hasConcept C2780745583 @default.
• W2103647780 hasConcept C2780902209 @default.
• W2103647780 hasConcept C2780948078 @default.
• W2103647780 hasConcept C43554185 @default.
• W2103647780 hasConcept C535046627 @default.
• W2103647780 hasConcept C71924100 @default.
• W2103647780 hasConcept C90924648 @default.
• W2103647780 hasConcept C98274493 @default.
• W2103647780 hasConceptScore W2103647780C126322002 @default.
• W2103647780 hasConceptScore W2103647780C126894567 @default.
• W2103647780 hasConceptScore W2103647780C134018914 @default.
• W2103647780 hasConceptScore W2103647780C142724271 @default.
• W2103647780 hasConceptScore W2103647780C197934379 @default.
• W2103647780 hasConceptScore W2103647780C203092338 @default.
• W2103647780 hasConceptScore W2103647780C204787440 @default.
• W2103647780 hasConceptScore W2103647780C27081682 @default.
• W2103647780 hasConceptScore W2103647780C2778163477 @default.
• W2103647780 hasConceptScore W2103647780C2778375690 @default.
• W2103647780 hasConceptScore W2103647780C2778657065 @default.
• W2103647780 hasConceptScore W2103647780C2778849439 @default.
• W2103647780 hasConceptScore W2103647780C2780072125 @default.

• next